{'fraction_non_alphanumeric': 0.028985507246376812, 'fraction_numerical': 0.007246376811594203, 'mean_word_length': 5.518867924528302, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
18F-FDG PET/CT in evaluation of radiofrequency ablation of liver metastasis.

Image-guided radiofrequency ablation (RFA) is a minimally invasive therapy option in the treatment of primary and secondary hepatic malignancies, which are not suitable for surgery/chemotherapy, and more recently, for tumors with limited hepatic involvement and solitary liver metastasis. Accurate assessment of treatment response after RFA remains a concern. Conventional imaging modalities have limitations of differentiation between residual/recurrence from post-RFA changes. We illustrate images of 3 patients in whom (18)F-FDG PET/CT was used for response assessment and restaging after RFA in liver tumors.